Search results for "Development"

showing 10 items of 26949 documents

2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors

2016

International audience; 2,3-Dihydrobenzofurans are proposed as privileged structures and used as chemical platform to design small compound libraries. By combining molecular docking calculations and experimental verification of biochemical interference, we selected some potential inhibitors of microsomal prostaglandin E2 synthase (mPGES)-1. Starting from low affinity natural product 1, by our combined approach we identified the compounds 19 and 20 with biological activity in the low micromolar range. Our data suggest that the 2,3-dihydrobenzofuran derivatives might be suitable bioinspired lead compounds for development of new generation mPGES-1 inhibitors with increased affinity.

0301 basic medicine300323-Dihydrobenzofuran privileged structure; Cancer; Inflammation; Molecular docking; mPGES-1 inhibitors; Biochemistry; Clinical Biochemistry; Molecular Biology; Molecular Medicine; Organic Chemistry; Drug Discovery3003 Pharmaceutical Science; 3003Amino Acid MotifsClinical BiochemistryGene ExpressionPharmaceutical Science01 natural sciencesClinical biochemistryBiochemistry[ CHIM ] Chemical SciencesProtein Structure Secondary[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compoundLow affinityDrug DiscoveryEnzyme Inhibitors23-Dihydrobenzofuran privileged structure; Molecular docking; mPGES-1 inhibitors; Cancer; InflammationProstaglandin-E SynthasesCancerAnti-Inflammatory Agents Non-SteroidalBiological activityProto-Oncogene Proteins c-metIntramolecular OxidoreductasesMolecular Docking SimulationMolecular dockingMolecular Medicinelipids (amino acids peptides and proteins)Cell SurvivalStereochemistryMolecular Sequence Data2Antineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer3-Dihydrobenzofuran privileged structureInhibitory Concentration 50Structure-Activity Relationship03 medical and health sciencesCell Line TumorMicrosomesHumans[CHIM]Chemical SciencesMolecular BiologyBenzofuransInflammationNatural product010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryEpithelial CellsmPGES-1 inhibitorsCombinatorial chemistryCombined approach0104 chemical sciences030104 developmental biologychemistryDrug DesignDrug Screening Assays Antitumor
researchProduct

Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment

2018

Standard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, s…

0301 basic medicine3003Lung NeoplasmsCancer therapymedicine.medical_treatmentPharmaceutical ScienceOncolytic viruseschemistry.chemical_compoundpaclitaxelkeuhkosyöpä0302 clinical medicineMedicineMice Inbred BALB CExtracellular vesiclesCHEMOTHERAPYCombined Modality Therapy3. Good healthxenograft animal modelPaclitaxelLiver317 Pharmacy030220 oncology & carcinogenesisonkolyyttiset viruksetcancer therapyFemaleLung canceronkolyyttinen virushoitoOncolytic adenovirusEFFICIENCYPaclitaxelCancer therapy; Drug delivery; Extracellular vesicles; Lung cancer; Oncolytic viruses; Paclitaxel; Xenograft animal model; 30033122 CancersMice NudeXenograft animal modelta3111OVARIAN-CANCERVIROTHERAPY03 medical and health sciencesCell Line TumorAnimalsHumansVirotherapyLung cancerChemotherapyADENOVIRUS RECEPTORsyöpähoidotbusiness.industryta1182CancerENDOSTATINmedicine.diseaseta3122Antineoplastic Agents PhytogenicGENEOncolytic virusMODELlung cancer030104 developmental biologychemistryviroterapiaDrug deliveryCELLSdrug deliveryCancer researchbusinessOvarian cancersolunulkoiset vesikkelitSpleen
researchProduct

Indicaxanthin from Opuntia Ficus Indica (L. Mill) impairs melanoma cell proliferation, invasiveness, and tumor progression.

2018

Abstract Background: A strong, reciprocal crosstalk between inflammation and melanoma has rigorously been demonstrated in recent years, showing how crucial is a pro-inflammatory microenvironment to drive therapy resistance and metastasis. Purpose: We investigated on the effects of Indicaxanthin, a novel, anti-inflammatory and bioavailable phytochemical from Opuntia Ficus Indica fruits, against human melanoma both in vitro and in vivo. Study Design and Methods: The effects of indicaxanthin were evaluated against the proliferation of A375 human melanoma cell line and in a mice model of cutaneous melanoma. Cell proliferation was assessed by MTT assay, apoptosis by Annexin V-Fluorescein Isothio…

0301 basic medicine3003MaleSkin NeoplasmsPyridinesPyridinePhytochemicalsMelanoma ExperimentalPharmaceutical ScienceIndicaxanthinApoptosisBcl-2 B cell lymphoma gene-2 (Bcl-2)chemistry.chemical_compoundMice0302 clinical medicineOpuntia Ficus Indica (L.Mill)Settore BIO/10 - BiochimicaDrug DiscoveryCXCL1 chemokine (C-X-C motif) ligand 1MelanomaNF-κB nuclear factor kappa BMTT 3-[45-dimethyltiazol-2-yl]-25-diphenyl tetrazolium bromideMelanomaNF-kappa BOpuntiaComplementary and Alternative Medicine2708 DermatologyBetaxanthinsCXCL1030220 oncology & carcinogenesisMolecular MedicinePhC phytochemicalGrowth inhibitionIndicaxanthinHumanBiologyPhytochemicalNHEM normal human epidermal melanocyte03 medical and health sciencesc-FLIP FLICE-inhibitory proteinIn vivoCell Line TumormedicineAnimalsHumansNeoplasm InvasivenessSkin NeoplasmCell ProliferationNeoplasm InvasiveneInflammationPharmacologyCell growthAnimalDrug Discovery3003 Pharmaceutical ScienceApoptosimedicine.diseaseMice Inbred C57BL030104 developmental biologyComplementary and alternative medicinechemistryTumor progressionList of Abbrevations: AxV-FITC annexin V-fluorescein isothiocyanateBetaxanthinFruitCutaneous melanomaCancer researchPI propidium iodide PIPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Engineering approaches in siRNA delivery.

2017

siRNAs are very potent drug molecules, able to silence genes involved in pathologies development. siRNAs have virtually an unlimited therapeutic potential, particularly for the treatment of inflammatory diseases. However, their use in clinical practice is limited because of their unfavorable properties to interact and not to degrade in physiological environments. In particular they are large macromolecules, negatively charged, which undergo rapid degradation by plasmatic enzymes, are subject to fast renal clearance/hepatic sequestration, and can hardly cross cellular membranes. These aspects seriously impair siRNAs as therapeutics. As in all the other fields of science, siRNAs management ca…

0301 basic medicine3003siRNAs Delivery vectors in vitro models Mathematical modeling Physical modelingDelivery vectors; In vitro models; Mathematical modeling; Physical modeling; SiRNAs; 3003Pharmaceutical ScienceNanotechnology02 engineering and technologyComputational biologyBiology03 medical and health sciencesDrug Delivery SystemsHumanssiRNAs; Delivery vectors; in vitro models; Mathematical modeling; Physical modelingRNA Small Interferingin vitro modelsPhysical modelingSettore ING-IND/34 - Bioingegneria IndustrialeHydrogelsDelivery vectorsModels Theoretical021001 nanoscience & nanotechnologyDelivery vectorsiRNAsClinical PracticeHydrogel030104 developmental biologyin vitro modelsiRNAMathematical modeling0210 nano-technologyBlood streamDrug Delivery SystemClearanceHumanInternational journal of pharmaceutics
researchProduct

A Natural Xenogeneic Endometrial Extracellular Matrix Hydrogel Toward Improving Current Human in vitro Models and Future in vivo Applications

2021

Decellularization techniques support the creation of biocompatible extracellular matrix hydrogels, providing tissue-specific environments for both in vitro cell culture and in vivo tissue regeneration. We obtained endometrium derived from porcine decellularized uteri to create endometrial extracellular matrix (EndoECM) hydrogels. After decellularization and detergent removal, we investigated the physicochemical features of the EndoECM, including gelation kinetics, ultrastructure, and proteomic profile. The matrisome showed conservation of structural and tissue-specific components with low amounts of immunoreactive molecules. EndoECM supported in vitro culture of human endometrial cells in t…

0301 basic medicine3D cultureHistologyStromal celllcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyExtracellular matrix03 medical and health sciencesTissue engineeringIn vivolcsh:TP248.13-248.65endometriumOriginal ResearchMatrigelDecellularizationextracellular matrix hydrogelsChemistryBioengineering and Biotechnology021001 nanoscience & nanotechnologyCell biology030104 developmental biologytissue engineeringSelf-healing hydrogelsdecellularizationStem cell0210 nano-technologyBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds

2017

The synthesis, the antitumor activity, the SAR and, whenever described, the possible mode of action of 1,2,4-triazine derivatives, their N-oxides, N,. N'-dioxides as well as the benzo- and hetero-fused systems are reported. Herein are treated derivatives disclosed to literature from the beginning of this century up to 2016. Among the three possible triazine isomers, 1,2,4-triazines are the most studied ones and many derivatives having remarkable antitumor activity have been reported in the literature and also patented reaching advanced phases of clinical trials.

0301 basic medicine4-benzotriazine124-triazineAntineoplastic AgentsChemistry Techniques SyntheticAntiproliferative activity01 natural sciences03 medical and health scienceschemistry.chemical_compoundNeoplasmsDrug DiscoveryOrganic chemistryAnimalsHumans124-triazineMode of action124-benzotriazineTriazineAntitumor activityPharmacology010405 organic chemistryChemistryTriazinesNitrogen heterocyclesDrug Discovery3003 Pharmaceutical Science1; 2; 4-benzotriazine; 1; 2; 4-triazine; Antiproliferative activity; Antitumor activity; Nitrogen heterocycles; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic ChemistryOrganic ChemistryGeneral MedicineCombinatorial chemistrySettore CHIM/08 - Chimica Farmaceutica0104 chemical sciences030104 developmental biologyNitrogen heterocycleDrug Screening Assays AntitumorAntitumor activity
researchProduct

Monitoring B-cell repopulation after depletion therapy in neurologic patients.

2017

ObjectiveTo determine the factors that influence B-cell repopulation after B-cell depletion therapy in neurologic patients and derive recommendations for monitoring and dosing of patients.MethodsIn this study, we determined the association of body surface area (BSA; calculated by body weight and height with the Dubois formula), sex, pretreatment therapy, age, CSF data, and white blood cell counts with the risk and timing of B-cell repopulation, defined as 1% CD19+ cells (of total lymphocytes), following 87 B cell–depleting anti-CD20 treatment cycles of 45 neurologic patients (28 women; mean age ± SD, 44.5 ± 15.0 years).ResultsPatients with a larger BSA had a higher probability to reach 1% C…

0301 basic medicine40medicine.medical_specialty41132LymphocyteUrologyCD19Article03 medical and health sciences0302 clinical medicineWhite blood cellMedicineDosingAdverse effectB cellBody surface areabiologybusiness.industry14323030104 developmental biologymedicine.anatomical_structureNeurologybiology.proteinRepopulationNeurology (clinical)business030217 neurology & neurosurgeryNeurology(R) neuroimmunologyneuroinflammation
researchProduct

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS

2018

ObjectiveTo describe a case of glial fibrillary acidic protein (GFAP)α immunoglobulin G (IgG)-associated encephalitis in a patient referred to us with MS on daclizumab treatment and to summarize characteristics of 5 additional recent German MS cases of serious encephalitis along with a previously published American case of CNS vasculitis associated with daclizumab.MethodsEvaluation of cause, clinical symptoms, and treatment response.ResultsThe 6 patients included 4 women and 2 men. The median age at onset was 38 years (range 32–51 years). Clinical presentation was marked by progressing neuropsychologic and/or neurologic deficits. Additional drug rash with eosinophilia was seen in 3 patients…

0301 basic medicine41132medicine.disease_causeArticleImmunoglobulin GAutoimmunity03 medical and health sciences0302 clinical medicineDaclizumabmedicineEosinophiliaPleocytosisbiologyGlial fibrillary acidic proteinbusiness.industrymedicine.disease030104 developmental biologyNeurologyImmunologybiology.proteinNeurology (clinical)medicine.symptomAntibodybusiness030217 neurology & neurosurgeryEncephalitismedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

TPP2 mutation associated with sterile brain inflammation mimicking MS

2018

ObjectiveTo ascertain the genetic cause of a consanguineous family from Syria suffering from a sterile brain inflammation mimicking a mild nonprogressive form of MS.MethodsWe used homozygosity mapping and next-generation sequencing to detect the disease-causing gene in the affected siblings. In addition, we performed RNA and protein expression studies, enzymatic activity assays, immunohistochemistry, and targeted sequencing of further MS cases from Austria, Germany, Canada and Jordan.ResultsIn this study, we describe the identification of a homozygous missense mutation (c.82T>G, p.Cys28Gly) in the tripeptidyl peptidase II (TPP2) gene in all 3 affected siblings of the family. Sequencing o…

0301 basic medicine41132medicine.disease_causeMajor histocompatibility complexArticle03 medical and health sciencesExon0302 clinical medicineGene expressionmedicineMissense mutationGeneGenetics (clinical)Medicinsk genetikMutationbiologyTripeptidyl peptidase IIDisease gene identificationMolecular biology3. Good health030104 developmental biologybiology.proteinNeurology (clinical)Medical Genetics030217 neurology & neurosurgeryNeurology Genetics
researchProduct

Implant Abutment Cleaning by Plasma of Argon: 5-Year Follow-Up of a Randomized Controlled Trial.

2015

Contamination of implant abutments could potentially influence the peri-implant tissue inflammatory response. The aim of the present study is to assess the radiographic bone changes around customized, platform-switched abutments placed according to the "one-abutment-one-time" protocol, with and without plasma of argon cleaning treatment.Thirty healthy patients with thin gingival biotype (1 mm) and history of periodontal disease received one maxillary implant each. Immediately before abutment connection, patients were randomly assigned to control group (cleaning protocol by steaming) or test group (plasma of argon treatment). Outcome measures were: 1) success rate of implants and prostheses;…

0301 basic medicine5 year follow upRadiographyAbutmentAlveolar Bone LossDentistryDental AbutmentsOsseointegrationlaw.invention03 medical and health sciences0302 clinical medicineDental Implants Single-ToothDental AbutmentsRandomized controlled triallawestheticsMedicineHumanstitaniumArgondental implant platform switchingbusiness.industry030206 dentistryArgon; bone resorption; dental implant-abutment interface; dental implant platform switching; esthetics; titanium.dental implant-abutment interface030104 developmental biologyPeriodonticsImplantbusinessbone resorptionImplant abutmentFollow-Up StudiesJournal of periodontology
researchProduct